Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906416 | 0.90 | ELANE (0.49) | TSHRELANEF2HTR1ADRD2 | |
| SCHEMBL7907404 | 0.82 | ALOX5 (0.54) | ELANEF2LMNA | |
| SCHEMBL18906399 | 0.82 | ELANE (0.43) | ELANEF2HTR1ADRD2KDM4E | |
| SCHEMBL6819629 | 0.81 | ELANE (0.47) | TSHRELANEF2HTR1ADRD2 | |
| SCHEMBL16064489 | 0.81 | USP28 (0.57) | ELANEF2HTTRAB9ASMN1; SMN2 | |
| SCHEMBL2394733 | 0.81 | L3MBTL1 (0.48) | ELANEF2HTR1ADRD2L3MBTL1 | |
| SCHEMBL9376228 | 0.81 | PTGER1 (0.50) | ELANEF2HTR1ADRD2L3MBTL1 | |
| SCHEMBL2853160 | 0.81 | APP (0.49) | ELANEF2HTR1ADRD2L3MBTL1 | |
| SCHEMBL560896 | 0.81 | MRGPRX4 (0.54) | ELANEF2NPC1TP53RAB9A | |
| SCHEMBL692555 | 0.79 | HTR1A (0.67) | ELANEF2HTR1ADRD2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| EP-1954673-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | Sanofi-Aventis Deutschland GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007059871-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | CYP46A1, GPR119, DHCR7 | TSHR 1869/4885ELANE 3021/4885F2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.